APA
Bachanova V., Marks D. I., Zhang M., Wang H., de Lima M., Aljurf M. D., Arellano M., Artz A. S., Bacher U., Cahn J., Chen Y., Copelan E. A., Drobyski W. R., Gale R. P., Greer J. P., Gupta V., Hale G. A., Kebriaei P., Lazarus H. M., Lewis I. D., Lewis V. A., Liesveld J. L., Litzow M. R., Loren A. W., Miller A. M., Norkin M., Oran B., Pidala J., Rowe J. M., Savani B. N., Saber W., Vij R., Waller E. K., Wiernik P. H. & Weisdorf D. J. (20140430). Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. : Leukemia.
Chicago
Bachanova V, Marks D I, Zhang M-J, Wang H, de Lima M, Aljurf M D, Arellano M, Artz A S, Bacher U, Cahn J-Y, Chen Y-B, Copelan E A, Drobyski W R, Gale R P, Greer J P, Gupta V, Hale G A, Kebriaei P, Lazarus H M, Lewis I D, Lewis V A, Liesveld J L, Litzow M R, Loren A W, Miller A M, Norkin M, Oran B, Pidala J, Rowe J M, Savani B N, Saber W, Vij R, Waller E K, Wiernik P H and Weisdorf D J. 20140430. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. : Leukemia.
Harvard
Bachanova V., Marks D. I., Zhang M., Wang H., de Lima M., Aljurf M. D., Arellano M., Artz A. S., Bacher U., Cahn J., Chen Y., Copelan E. A., Drobyski W. R., Gale R. P., Greer J. P., Gupta V., Hale G. A., Kebriaei P., Lazarus H. M., Lewis I. D., Lewis V. A., Liesveld J. L., Litzow M. R., Loren A. W., Miller A. M., Norkin M., Oran B., Pidala J., Rowe J. M., Savani B. N., Saber W., Vij R., Waller E. K., Wiernik P. H. and Weisdorf D. J. (20140430). Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. : Leukemia.
MLA
Bachanova V, Marks D I, Zhang M-J, Wang H, de Lima M, Aljurf M D, Arellano M, Artz A S, Bacher U, Cahn J-Y, Chen Y-B, Copelan E A, Drobyski W R, Gale R P, Greer J P, Gupta V, Hale G A, Kebriaei P, Lazarus H M, Lewis I D, Lewis V A, Liesveld J L, Litzow M R, Loren A W, Miller A M, Norkin M, Oran B, Pidala J, Rowe J M, Savani B N, Saber W, Vij R, Waller E K, Wiernik P H and Weisdorf D J. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. : Leukemia. 20140430.